Menu

  1. Home
  2.  / 
  3. Vitreo Retinal Diseases - I, Free Paper
  4.  / 
  5. FP0786 : comparative study on role of innovator bevacizumab vs biosimilar Bevacizumab in management of ROP.

Share this post

Chief & Presenting Author: Dr.Rahul Prasad

Co Author(s): Dr. Jennifer Gagrai, Dr. Varsha Bhagat

Abstract

PURPOSE :To study and compare the role of innovator bevacizumab with an Indian biosimilar Bevacizumab for the management of type 1 ROP. MATERIAL AND METHOD :A retrospective single center interventional study was carried out on 72 eyes having type 1 ROP. 36 eyes having type 1 ROP were treated with innovator bevacizumab and the second group of 36 eyes were managed by an Indian biosimilar bevacizumab. RESULT: Complete regression of ROP was seen in 68.06% of babies receiving innovator bevacizumab and 67.92% of babies receiving the Indian biosimilar bevacizumab monotherapy. In those babies having residual ROP , complete regression was seen in both group after adding laser photocoagulation. The study population experienced no ocular or systemic adverse effects in either group. CONCLUSION :Our study demonstrated that both innovator bevacizumab and our Indian biosimilar bevacizumab offer similar benefit in type 1 ROP.